Injectable triamcinolone suspension approved for use in eye surgery

December 15, 2007

The FDA has approved a formulation of triamcinolone acetonide injectable suspension 40 mg/ml (Triesence, Alcon) for visualization during vitrectomy and treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Rockville, MD-The FDA has approved a formulation of triamcinolone acetonide injectable suspension 40 mg/ml (Triesence, Alcon), a preservative-free synthetic corticosteroid, for visualization during vitrectomy and treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

The product's active ingredient, triamcinolone, has been used for many years to treat retinal disease. The new approval, however, brings ophthalmologists a sterile, preservative-free formulation of the compound specifically developed for use in the eye to treat various retinal inflammatory conditions, according to a prepared statement from Alcon.